Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia

Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of clinical immunology 2022-08, Vol.42 (6), p.1107-1110
Hauptverfasser: Chauvineau-Grenier, Angélique, Bastard, Paul, Casanova, Jean-Laurent, Rossi, Benjamin
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Monoclonal, Humanized - therapeutic use
Autoantibodies
Biomedical and Life Sciences
Biomedicine
COVID-19
COVID-19 Drug Treatment
Humans
Immunology
Infectious Diseases
Internal Medicine
Letter to Editor
Medical Microbiology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1110
container_issue 6
container_start_page 1107
container_title Journal of clinical immunology
container_volume 42
creator Chauvineau-Grenier, Angélique
Bastard, Paul
Casanova, Jean-Laurent
Rossi, Benjamin
description
doi_str_mv 10.1007/s10875-022-01295-5
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9177133</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2674753999</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-842602e80796396eb6fcccc94c5ab1fa6ec35217054a4e9a6040f47d8e5cb1c03</originalsourceid><addsrcrecordid>eNp9kU1vEzEYhC0EomnhD3BAlrhw2eJvry9IIbQQqbQcAlfL67ybutq1w3oXlP563Ka0lAO--DDPjD0ahF5RckwJ0e8yJbWWFWGsIpQZWcknaEal5hWThj1FM8I0rQwV7AAd5nxFCOGKyefogEullVT1DHXzaUwujqFJ6wAZn8M0Dq4L1yFu8Gq3BbzEy_PTjL-4Hf4AeJ5z8sGNsMa_wniJT9o2eOd3OLV4VZTinHrX4BDx4uL78mNFDf4aYepTDO4Feta6LsPLu_sIfTs9WS0-V2cXn5aL-VnlhRZjVQumCIOaaKO4UdCo1pdjhJeuoa1T4LlkVBMpnADjFBGkFXpdg_QN9YQfoff73O3U9LD2EG862e0QejfsbHLBPlZiuLSb9NMaqjXlvAS8vQsY0o8J8mj7kD10nYuQpmyZ0kJLbowp6Jt_0Ks0DbHUs0wzWhDJdaHYnvJDynmA9v4zlNibMe1-TFvGtLdjWllMr_-ucW_5s14B-B7IRYobGB7e_k_sb1BNqg4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2721999537</pqid></control><display><type>article</type><title>Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Chauvineau-Grenier, Angélique ; Bastard, Paul ; Casanova, Jean-Laurent ; Rossi, Benjamin</creator><creatorcontrib>Chauvineau-Grenier, Angélique ; Bastard, Paul ; Casanova, Jean-Laurent ; Rossi, Benjamin</creatorcontrib><identifier>ISSN: 0271-9142</identifier><identifier>EISSN: 1573-2592</identifier><identifier>DOI: 10.1007/s10875-022-01295-5</identifier><identifier>PMID: 35676568</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Antibodies, Monoclonal, Humanized - therapeutic use ; Autoantibodies ; Biomedical and Life Sciences ; Biomedicine ; COVID-19 ; COVID-19 Drug Treatment ; Humans ; Immunology ; Infectious Diseases ; Internal Medicine ; Letter to Editor ; Medical Microbiology</subject><ispartof>Journal of clinical immunology, 2022-08, Vol.42 (6), p.1107-1110</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-842602e80796396eb6fcccc94c5ab1fa6ec35217054a4e9a6040f47d8e5cb1c03</citedby><cites>FETCH-LOGICAL-c474t-842602e80796396eb6fcccc94c5ab1fa6ec35217054a4e9a6040f47d8e5cb1c03</cites><orcidid>0000-0001-9467-744X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10875-022-01295-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10875-022-01295-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35676568$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chauvineau-Grenier, Angélique</creatorcontrib><creatorcontrib>Bastard, Paul</creatorcontrib><creatorcontrib>Casanova, Jean-Laurent</creatorcontrib><creatorcontrib>Rossi, Benjamin</creatorcontrib><title>Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia</title><title>Journal of clinical immunology</title><addtitle>J Clin Immunol</addtitle><addtitle>J Clin Immunol</addtitle><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Autoantibodies</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>COVID-19</subject><subject>COVID-19 Drug Treatment</subject><subject>Humans</subject><subject>Immunology</subject><subject>Infectious Diseases</subject><subject>Internal Medicine</subject><subject>Letter to Editor</subject><subject>Medical Microbiology</subject><issn>0271-9142</issn><issn>1573-2592</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU1vEzEYhC0EomnhD3BAlrhw2eJvry9IIbQQqbQcAlfL67ybutq1w3oXlP563Ka0lAO--DDPjD0ahF5RckwJ0e8yJbWWFWGsIpQZWcknaEal5hWThj1FM8I0rQwV7AAd5nxFCOGKyefogEullVT1DHXzaUwujqFJ6wAZn8M0Dq4L1yFu8Gq3BbzEy_PTjL-4Hf4AeJ5z8sGNsMa_wniJT9o2eOd3OLV4VZTinHrX4BDx4uL78mNFDf4aYepTDO4Feta6LsPLu_sIfTs9WS0-V2cXn5aL-VnlhRZjVQumCIOaaKO4UdCo1pdjhJeuoa1T4LlkVBMpnADjFBGkFXpdg_QN9YQfoff73O3U9LD2EG862e0QejfsbHLBPlZiuLSb9NMaqjXlvAS8vQsY0o8J8mj7kD10nYuQpmyZ0kJLbowp6Jt_0Ks0DbHUs0wzWhDJdaHYnvJDynmA9v4zlNibMe1-TFvGtLdjWllMr_-ucW_5s14B-B7IRYobGB7e_k_sb1BNqg4</recordid><startdate>20220801</startdate><enddate>20220801</enddate><creator>Chauvineau-Grenier, Angélique</creator><creator>Bastard, Paul</creator><creator>Casanova, Jean-Laurent</creator><creator>Rossi, Benjamin</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9467-744X</orcidid></search><sort><creationdate>20220801</creationdate><title>Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia</title><author>Chauvineau-Grenier, Angélique ; Bastard, Paul ; Casanova, Jean-Laurent ; Rossi, Benjamin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-842602e80796396eb6fcccc94c5ab1fa6ec35217054a4e9a6040f47d8e5cb1c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Autoantibodies</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>COVID-19</topic><topic>COVID-19 Drug Treatment</topic><topic>Humans</topic><topic>Immunology</topic><topic>Infectious Diseases</topic><topic>Internal Medicine</topic><topic>Letter to Editor</topic><topic>Medical Microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chauvineau-Grenier, Angélique</creatorcontrib><creatorcontrib>Bastard, Paul</creatorcontrib><creatorcontrib>Casanova, Jean-Laurent</creatorcontrib><creatorcontrib>Rossi, Benjamin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chauvineau-Grenier, Angélique</au><au>Bastard, Paul</au><au>Casanova, Jean-Laurent</au><au>Rossi, Benjamin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia</atitle><jtitle>Journal of clinical immunology</jtitle><stitle>J Clin Immunol</stitle><addtitle>J Clin Immunol</addtitle><date>2022-08-01</date><risdate>2022</risdate><volume>42</volume><issue>6</issue><spage>1107</spage><epage>1110</epage><pages>1107-1110</pages><issn>0271-9142</issn><eissn>1573-2592</eissn><cop>New York</cop><pub>Springer US</pub><pmid>35676568</pmid><doi>10.1007/s10875-022-01295-5</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0001-9467-744X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0271-9142
ispartof Journal of clinical immunology, 2022-08, Vol.42 (6), p.1107-1110
issn 0271-9142
1573-2592
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9177133
source MEDLINE; SpringerNature Journals
subjects Antibodies, Monoclonal, Humanized - therapeutic use
Autoantibodies
Biomedical and Life Sciences
Biomedicine
COVID-19
COVID-19 Drug Treatment
Humans
Immunology
Infectious Diseases
Internal Medicine
Letter to Editor
Medical Microbiology
title Autoantibodies Neutralizing Type I INFs May Be Associated with Efficacy of Tocilizumab in COVID-19 Pneumonia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T18%3A37%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autoantibodies%20Neutralizing%20Type%20I%20INFs%20May%20Be%20Associated%20with%20Efficacy%20of%20Tocilizumab%20in%20COVID-19%20Pneumonia&rft.jtitle=Journal%20of%20clinical%20immunology&rft.au=Chauvineau-Grenier,%20Ang%C3%A9lique&rft.date=2022-08-01&rft.volume=42&rft.issue=6&rft.spage=1107&rft.epage=1110&rft.pages=1107-1110&rft.issn=0271-9142&rft.eissn=1573-2592&rft_id=info:doi/10.1007/s10875-022-01295-5&rft_dat=%3Cproquest_pubme%3E2674753999%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2721999537&rft_id=info:pmid/35676568&rfr_iscdi=true